ABUS vs AMN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ABUS exhibits severe financial distress signals with a Piotroski F-Score of 0/9, indicating extreme weakness in operational and financial health. The company reports massive negative margins, declining revenue, and unprofitable operations, with no meaningful cash flow or profitability. While the low debt-to-equity ratio and high current ratios suggest strong liquidity, they are likely inflated by non-operational cash reserves. The absence of a Graham Number and intrinsic value estimate reflects a lack of sustainable earnings, and the stock trades at a premium valuation despite deteriorating fundamentals. Analysts offer no consensus, and insider activity is neutral, reinforcing a lack of confidence.
The company exhibits severe financial distress with a Piotroski F-Score of just 2/9, indicating weak fundamental health. Despite recent earnings surprises and short-term EPS growth, the business is unprofitable (negative profit margin and ROE), leveraged (Debt/Equity of 1.37), and has declining revenues. Valuation metrics like a high Forward P/E of 30.31 and low Price/Sales of 0.29 reflect inconsistent pricing signals, while the stock has lost over 70% of its value in the past five years. The absence of an Altman Z-Score due to insufficient data further raises concerns about financial stability.
Compare Another Pair
Related Comparisons
ABUS vs AMN: Head-to-Head Comparison
This page compares Arbutus Biopharma Corporation (ABUS) and AMN Healthcare Services, Inc. (AMN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.